Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - alirocumab -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - alirocumab -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - alirocumab -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - alirocumab -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - alirocumab -

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - alirocumab 150 mg/ml - solution for injection - 150 mg/ml - active: alirocumab 150 mg/ml excipient: histidine polysorbate 20 sucrose water for injection - eliriduc is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet: - in combination with a statin or statin with other lipid lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin or, - alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated. the effect of eliriduc on cardiovascular morbidity and mortality has not yet been determined.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - alirocumab 75 mg/ml - solution for injection - 75 mg/ml - active: alirocumab 75 mg/ml excipient: histidine polysorbate 20 sucrose water for injection - eliriduc is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet: - in combination with a statin or statin with other lipid lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin or, - alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated. the effect of eliriduc on cardiovascular morbidity and mortality has not yet been determined.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - alirocumab 150 mg/ml - solution for injection - 150 mg/ml - active: alirocumab 150 mg/ml excipient: histidine polysorbate 20 sucrose water for injection - golyra is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet: - in combination with a statin or statin with other lipid lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin or, - alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated. the effect of golyra on cardiovascular morbidity and mortality has not yet been determined.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - alirocumab 75 mg/ml - solution for injection - 75 mg/ml - active: alirocumab 75 mg/ml excipient: histidine polysorbate 20 sucrose water for injection - golyra is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet: - in combination with a statin or statin with other lipid lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin or, - alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated. the effect of golyra on cardiovascular morbidity and mortality has not yet been determined.

Νότια Αφρική - Αγγλικά - South African Health Products Regulatory Authority (SAHPRA)

sanofi-aventis south africa (pty) ltd - injection - see ingredients - each 1,0 ml solution contains alirocumab 75,0 mg